1.Friedman SL. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-50
2.Friedman SL. 2003. Liver fibrosis -- from bench to bedside. J Hepatol 38 Suppl 1: S38-53
3.Gines P, Cardenas A, Arroyo V, Rodes J. 2004. Management of cirrhosis and ascites. N Engl J Med 350: 1646-54
4.Iredale JP. 2003. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 327: 143-7
5.Schuppan D, Ruehl M, Somasundaram R, Hahn EG. 2001. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21: 351-72
6.Friedman SL. 1993. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 328: 1828-35
7.Gressner AM, Lotfi S, Gressner G, Haltner E, Kropf J. 1993. Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J Hepatol 19: 117-32
8.Shi Z, Wakil AE, Rockey DC. 1997. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 94: 10663-8
9.Hemmann S, Graf J, Roderfeld M, Roeb E. 2007. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46: 955-75
10.Friedman SL, Roll FJ, Boyles J, Bissell DM. 1985. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 82: 8681-5
11.Geerts A. 2001. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311-35
12.PL W. 1995. Gray’s Anatomy：the anatomical basis of Medicine and surgery.
13.Kmiec Z. 2001. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161: III-XIII, 1-151
14.Hautekeete ML, Geerts A. 1997. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 430: 195-207
15.Tanikawa K. 1999. Liver Diseases And Hepatic Sinusoidal Cells: Springer-verlag 356 pp.
16.Senoo H. 2004. Structure and function of hepatic stellate cells. Med Electron Microsc 37: 3-15
17.Marra F. 1999. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31: 1120-30
18.Burt AD. 1999. Pathobiology of hepatic stellate cells. J Gastroenterol 34: 299-304
19.Friedman SL. 1996. Hepatic stellate cells. Prog Liver Dis 14: 101-30
20.Kurosaka K, Watanabe N, Kobayashi Y. 2001. Production of proinflammatory cytokines by resident tissue macrophages after phagocytosis of apoptotic cells. Cell Immunol 211: 1-7
21.Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. 1992. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 15: 234-43
22.Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N, Murphy G. 1996. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 24: 176-84
23.Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, Arthur MJ. 1995. Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology 22: 304-15
24.Arroyo V. 2002. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 1: 72-9
25.Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, Seki S, Kuroki T, Yoshizato K. 2000. Proteome analysis of rat hepatic stellate cells. Hepatology 32: 268-77
26.Sato M, Suzuki S, Senoo H. 2003. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 28: 105-12
27.Friedman SL, Yamasaki G, Wong L. 1994. Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J Biol Chem 269: 10551-8
28.Friedman SL, Roll FJ, Boyles J, Arenson DM, Bissell DM. 1989. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 264: 10756-62
29.Sohara N, Znoyko I, Levy MT, Trojanowska M, Reuben A. 2002. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 37: 214-21
30.Iredale JP. 2001. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 21: 427-36
31.Ramm GA, Britton RS, O''Neill R, Blaner WS, Bacon BR. 1995. Vitamin A-poor lipocytes: a novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts. Am J Physiol 269: G532-41
32.Ballardini G, Groff P, Badiali de Giorgi L, Schuppan D, Bianchi FB. 1994. Ito cell heterogeneity: desmin-negative Ito cells in normal rat liver. Hepatology 19: 440-6
33.Schmitt-Graff A, Desmouliere A, Gabbiani G. 1994. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch 425: 3-24
34.Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011-20
35.Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001-10
36.Arora G, Keeffe EB. 2007. Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy. Rev Gastroenterol Disord 7: 63-73
37.Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N. 2009. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 44: 864-70
38.Cho SW, Koh KH, Cheong JY, Lee MH, Hong SP, Yoo WD, Kim SO. 2010. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 17: 171-7
39.Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D. 2001. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35: 392-8
40.Wagner H SO, Seitz M, Abraham D. 1976. Sonnenbichler J.Silydianin und Silychristin, zwei isomere Silymarine aus Silybum marianum (Mariendistel). Z Naturforsch 31: 876-84
41.Dehmlow C, Erhard J, de Groot H. 1996. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23: 749-54
42.Mourelle M, Muriel P, Favari L, Franco T. 1989. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 3: 183-91
43.Jia JD BG, Bauer M, Ruehl M, Strefeld T, Riecken EO. 1998. Silymarin downregulates TIMP-1 and collagen I mRNA in rats with secondary biliary cirrhosis. Hepatology 28(suppl.): 546A
44.Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. 1993. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31: 456-60
45.Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. 1999. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29: 149-60
46.Kyo R, Nakahata N, Sakakibara I, Kubo M, Ohizumi Y. 1998. Effects of Sho-saiko-to, San''o-shashin-to and Scutellariae Radix on intracellular Ca2+ mobilization in C6 rat glioma cells. Biol Pharm Bull 21: 1067-71
47.Sakaida I, Hironaka K, Kimura T, Terai S, Yamasaki T, Okita K. 2004. Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci 74: 2251-63
48.Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Lin CC, Hsieh HY. 2004. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am J Chin Med 32: 195-207
49.Wang BJ, Liu CT, Tseng CY, Wu CP, Yu ZR. 2004. Hepatoprotective and antioxidant effects of Bupleurum kaoi Liu (Chao et Chuang) extract and its fractions fractionated using supercritical CO(2) on CCl(4)-induced liver damage. Food Chem Toxicol 42: 609-17
50.Kusunose M, Qiu B, Cui T, Hamada A, Yoshioka S, Ono M, Miyamura M, Kyotani S, Nishioka Y. 2002. Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats. Biol Pharm Bull 25: 1417-21
51.Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, Hsieh HY. 2005. The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat''s bile duct ligated model. J Ethnopharmacol 97: 7-13
52.Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T. 1995. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76: 743-9
53.Gibo Y NY, Takahashi N, Inada H, Nakagawa M, Usuda S, Nakano Y. 1994. Clinical study of Sho-saiko-to therapy to the Japanese patients with chronic hepatitis type C (CH-C). Prog Med 14: 217-9
54.Tajiri H, Kozaiwa K, Ozaki Y, Miki K, Shimuzu K, Okada S. 1991. Effect of sho-saiko-to(xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. Am J Chin Med 19: 121-9
55.Inao M, Mochida S, Matsui A, Eguchi Y, Yulutuz Y, Wang Y, Naiki K, Kakinuma T, Fujimori K, Nagoshi S, Fujiwara K. 2004. Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol 41: 584-91
56.Imanishi Y, Maeda N, Otogawa K, Seki S, Matsui H, Kawada N, Arakawa T. 2004. Herb medicine Inchin-ko-to (TJ-135) regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats. J Hepatol 41: 242-50
57.Sakaida I, Tsuchiya M, Kawaguchi K, Kimura T, Terai S, Okita K. 2003. Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 38: 762-9
58.Yamamoto M, Ogawa K, Morita M, Fukuda K, Komatsu Y. 1996. The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1. Hepatology 23: 552-9
59.Ikeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y, Tejima K, Nishikawa T, Watanabe N, Kitamura K, Isono T, Yahagi N, Noiri E, Inao M, Mochida S, Kume Y, Yatomi Y, Nakahara K, Omata M, Fujiwara K. 2006. The herbal medicine inchin-ko-to (TJ-135) induces apoptosis in cultured rat hepatic stellate cells. Life Sci 78: 2226-33
60.Editorial Committee of the Flora of Taiwan FoT. 2003. Flora of Taiwan.
61.Peng CI CC, Leu WP, Yen HF. 1998. Pluchea Cass. (Asteraceae: Inuleae) in Taiwan. Bot. Bull. Acad. Sin.: 287-97
62.陳虹妃. 2003. 氯化鈉對鯽魚膽切離葉片之影響. 國立高雄師範大學生物科學研究所碩士論文63.陳玉樹. 2002. 鹽與乾旱逆境對屋山頂火山地區植物分佈之影響. 國立高雄師範大學生物科學研究所碩士論文64.K.R. Kirtikar BDB. 1999. Indian Medicinal Plants: Dehradun and Delhi: International Book Distributors
65.Pramanik KC BP, Biswas R, Bandyopadhyay D, Mishra M,Chatterjee TK. 2006. Hypoglycemic and antihyperglycemic activity of leaf extract of Pluchea indica Less. Orient Pharm Exp Med 6: 232-6
66.Pramanik KC BR, Mitra A, Bandyopadhyay D, Mishra M, Chatterjee TK. 2007. Tissue Culture of the plant Pluchea indica (L.) Less. and Evaluation of Diuretic Potential of its Leaves. Orient Pharm Exp Med 7: 197-204
67.Sen T, Nag Chaudhuri AK. 1991. Antiinflammatory evaluation of a Pluchea indica root extract. J Ethnopharmacol 33: 135-41
68.Pal S NCA. 1989. Studies on the effect of Pluchea indica Less. root extract on gastroduodenal ulcer models in rats and guinea pig. Phytother Res 3: 156-8
69.Ria Biswas AD, Anupama Mitra, Subodh K. Roy , Pradip K. Dutta, Basudeb Achari, Sujata Ghosh Dastidar, Tapan K. Chatterjee*,. 2005. Isolation, purification and characterization of four pure compounds from the root extract of Pluchea indica (L.) Less. and the potentiality of the root extract and the pure compounds for antimicrobial activity. European Bulletin of Drug Research 13: 63–70
70.Sen T, Dhara AK, Bhattacharjee S, Pal S, Nag Chaudhuri AK. 2002. Antioxidant activity of the methanol fraction of Pluchea indica root extract. Phytother Res 16: 331-5
71.Thongpraditchote S, Matsumoto K, Temsiririrkkul R, Tohda M, Murakami Y, Watanabe H. 1996. Neuropharmacological actions of Pluchea indica Less root extract in socially isolated mice. Biol Pharm Bull 19: 379-83
72.Biswas R, Dutta PK, Achari B, Bandyopadhyay D, Mishra M, Pramanik KC, Chatterjee TK. 2007. Isolation of pure compound R/J/3 from Pluchea indica (L.) Less. and its anti-amoebic activities against Entamoeba histolytica. Phytomedicine 14: 534-7
73.Gomes A, Saha A, Chatterjee I, Chakravarty AK. 2007. Viper and cobra venom neutralization by beta-sitosterol and stigmasterol isolated from the root extract of Pluchea indica Less. (Asteraceae). Phytomedicine 14: 637-43
74.曹淑娟. 2007. 探討鯽魚膽根與葉之水萃物對癌細胞的影響. 國立中山大學生物科學系碩士在職專班碩士論文75.吳麗娟. 2009. 鯽魚膽水萃物對硫代乙醯胺誘發小鼠肝纖維化的保護作用. 國立中山大學生物科學系碩士在職專班碩士論文76.Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK. 2000. Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol 58: 1287-93
77.Lee KS, Buck M, Houglum K, Chojkier M. 1995. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 96: 2461-8
78.Bataller R, Brenner DA. 2001. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21: 437-51